GRAVES DISEASE OVERACTIVE THYROID MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Growing Awareness Propelling Earlier Diagnosis

Increased global focus on thyroid health in recent years has boosted awareness and detection rates for Graves' disease. Nowadays, people are more knowledgeable about symptoms of an overactive thyroid like unintended weight loss, palpitations, eye bulging, and others, thus, these people seek medical advice for evaluation. Moreover, diagnostic advancements have made it possible for doctors to identify thyroid abnormalities much earlier through sensitive blood tests and thyroid scans. This results in more Graves' disease cases being picked up at mild and moderate stages rather than at later severe phases. Growing number of specialized endocrinology centers and availability of expert doctors in both rural and urban areas have further strengthened healthcare access and diagnostic infrastructure. Population-wide screening programs for early thyroid issues have also been launched in several countries. Integrated with hyperlocal health outreach initiatives, these measures enables timely diagnosis of Graves' disease in communities.

• AbbVie Inc.
• Pfizer Inc.
• RLC LABS, Inc.
• Merck KGaA
• Eisai Co., Ltd.
• Novartis AG
• Mylan N.V.
• Aspen Pharmacare Holdings Ltd
• Sanofi
• GlaxoSmithKline plc
• AstraZeneca
• Horizon Therapeutics plc
• Alara Pharmaceutical Corporation
• Antares Pharma, Inc.
• Apitope Technology (Bristol) Ltd.
• IONIS Pharmaceuticals, Inc.
• Immunovant, Inc.
• HanAll Biopharma Co., Ltd.
• Cara Therapeutics